

**Adult CIRB - Late Phase Emphasis Meeting Agenda**

**March 6, 2025**

---

**I Continuing Review**

**A041703**, A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease (Version Date 02/07/24)

---

**II Continuing Review**

**10231**, NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study (Version Date 09/20/19)

---

**III Continuing Review**

**AMC-107**, A Phase 2 Trial of Ixazomib for Kaposi Sarcoma (Version Date 09/22/22)

---

**IV Continuing Review**

**EA2197**, Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial (Version Date 07/20/23)

---

**V Continuing Review**

**E1A11**, Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) (Version Date 10/21/20)

---

## **VI Continuing Review**

**EA4181**, A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients  $\leq$  70 years old with Untreated Mantle Cell Lymphoma (Version Date 03/29/24)

---

## **VII Continuing Review**

**GOG-0262**, A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel In Combination With Carboplatin With Or Without Concurrent and Consolidation Bevacizumab (NSC #704865, IND #113912) in the Treatment of Primary Stage II, III OR IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging To Evaluate Treatment Response in Patients Participating in GOG-0262 (Version Date 11/07/18)

---

## **VIII Continuing Review**

**S2200**, A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2) (Version Date 11/08/24)

---

## **IX Continuing Review**

**S2207**, Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapsed/Refractory Large B-Cell Lymphoma (Version Date 03/18/24)

---

## **X Continuing Review**

**S2210**, A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer with Germline BRCA1/2 Mutations (Version Date 06/07/23)

---